Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Clinical Trial ID NCT00878436

Rank	Title	Journal	Year	PubWeight™‹?›
1	Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.	Future Oncol	2011	1.34
2	Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.	ACS Chem Biol	2013	0.90
3	Targeting Histone Deacetylases in Diseases: Where Are We?	Antioxid Redox Signal	2014	0.88
4	Recent developments in prostate cancer biomarker research: therapeutic implications.	Br J Clin Pharmacol	2011	0.86
5	Emerging molecularly targeted therapies in castration refractory prostate cancer.	Prostate Cancer	2013	0.83
6	Molecular pathways: targeting ETS gene fusions in cancer.	Clin Cancer Res	2014	0.83
7	Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.	Transl Res	2014	0.78
8	Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.	Ther Adv Urol	2015	0.78
9	Translational and clinical implications of the genetic landscape of prostate cancer.	Nat Rev Clin Oncol	2016	0.76
10	Epigenetic modulators as therapeutic targets in prostate cancer.	Clin Epigenetics	2016	0.76